Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
Keyword Search Criteria: time-to-event returned 40 record(s)
|
Sunday, 07/29/2018
|
Regression Calibration to Address Error Prone Time-To-Event Outcomes
Eric Oh, University of Pennsylvania; Pamela A Shaw, University of Pennsylvania
|
Regression Calibration to Address Error Prone Time-To-Event Outcomes
Eric Oh, University of Pennsylvania; Pamela A Shaw, University of Pennsylvania
2:05 PM
|
Joint Modeling of Multiple Time-To-Event Outcomes
Shanshan Zhao, National Institute of Environmental Health Sciences; Ross Prentice, Fred Hutchinson Cancer Research Center
2:45 PM
|
Correlation Between the Time-To-Event Endpoints in Prostate Cancer Clinical Trials
Susan Li, Janssen R&D
3:05 PM
|
A Hybrid Approach for Prediction of Event Times in Double-Blind Clinical Trials
Ming Zhu, Sanofi Pasteur; Yunnan Xu, Virginia Tech; Zheng Su, Deerfield Institute
5:05 PM
|
Monday, 07/30/2018
|
Comparisons of Modeling Methods on Longitudinal and Survival Data: Identifying Use of Repeat Biomarker Measurements to Predict Time-To-Event Outcome in Cancer Research
Meng Ru, Icahn School of Medicine at Mount Sinai; Erin Moshier, Icahn School of Medicine at Mount Sinai; Madhu Mazumdar, Icahn School of Medicine at Mount Sinai
|
Maximum Likelihood Estimation of the K Parameter in the Poly-K Trend Test for Time-to-Event Data
Anna Korpak, VA ERIC; Barbara McKnight, University of Washington
|
Individualized Treatment for Time-To-Event Outcomes with BART
Brent Logan, Medical College of Wisconsin
8:35 AM
|
Pseduolikelihood for Clustered Time-To-Event Outcomes from Complex Surveys
Jing Wang
9:50 AM
|
Maximum Likelihood Estimation of the K Parameter in the Poly-K Trend Test for Time-to-Event Data
Anna Korpak, VA ERIC; Barbara McKnight, University of Washington
11:05 AM
|
Comparisons of Modeling Methods on Longitudinal and Survival Data: Identifying Use of Repeat Biomarker Measurements to Predict Time-To-Event Outcome in Cancer Research
Meng Ru, Icahn School of Medicine at Mount Sinai; Erin Moshier, Icahn School of Medicine at Mount Sinai; Madhu Mazumdar, Icahn School of Medicine at Mount Sinai
11:15 AM
|
Sample Size Determination Under Non-Proportional Hazards
Zhaowei Hua, Takeda Pharmaceuticals International Co.; Miao Yang, Oregon State University; Saran Vardhanabhuti, Takeda Pharmaceuticals
2:20 PM
|
Innovative Approaches to Deal with Delayed Treatment Effect, Cure Fraction and Treatment Switching in Time-To-Event Data in Cancer Immuno-Therapies
Carl Di Casoli, Halozyme Therapeutics; Alessandro Previtali, Celgene; Jonathan Jaeger, Celgene; Marie-Laure Casaebaig, Celgene
3:05 PM
|
A Simulation-Based Comparison Study About Different Methods Adjusting for the Bias of Treatment Non-Adherence
Jia Jia, AbbVie; Ying Zhang, Penn State College of Medicine; Jane Qian, Abbvie
3:20 PM
|
Penalized Shrinkage Estimation in Reduced-Rank Time-To-Event Data
Ananda Sen, University of Michigan
3:25 PM
|
Predictive Probability on Interim Analysis of Time-To-Event Endpoints with Delayed Treatment Effects
Matt Rosales, Astellas; Kentaro Takeda, Astellas Pharma Global Development, Inc.
3:35 PM
|
Tuesday, 07/31/2018
|
Methods for Combining Controlled and Uncontrolled Clinical Trials
Shuyan Sabrina Wan, Merck Research Lab; Yuan Feng, North Carolina State University; Hong Liu, Merck; Kenneth Koury, Pfizer
|
Use of Propensity Score and Disease Risk Score for Multiple Treatments with Time-To-Event Outcome
DI ZHANG, University of Pittsburgh; Jessica Kim, Division of Biometrics VII/Office of Biostatistics/CDER, FDA
|
Endpoint and Time-To-Event Analyzes in Interim Clinical Trial Reports
Scott Diegel, University of Wisconsin-Madison; Ryan Zea, University of Wisconsin-Madison; Melissa Schultz, University of Wisconsin-Madison
|
Sequential Parallel Comparison Design with Binary and Time-to-Event Outcomes
Rachel Silverman, Merck & Co.; Anastasia Ivanova, University of North Carolina, Chapel Hill; Jason P Fine, University of North Carolina at Chapel Hill
|
Statistical Precision of Time-to-Event Endpoint in Single Arm Observational Study Using Monte Carlo Simulation
Meijing Wu, AbbVie; Hongwei Wang, AbbVie Inc; Yabing Mai, AbbVie, Inc; Dajun Tian, Chiltern
|
A Machine Learning (ML) Approach to Prognostic and Predictive Covariate Identification for Subgroup Analysis and Hypotheses Generation
David A James, Novartis
|
Model Validation of Time-To-Event Analyzes via the Concordance Statistic
Samantha-Jo Caetano, McMaster University
|
Real-Time Study Milestone Projection in Clinical Trials with Time-To-Event Endpoints
Yanping Liu, Merck & Co.; Gang Jia, Merck & Co.
|
Model Validation of Time-To-Event Analyzes via the Concordance Statistic
Samantha-Jo Caetano, McMaster University
8:40 AM
|
Systematic Review of Test/Estimation Approach in Comparative Cancer Clinical Studies with Time-To-Event Outcomes
Miki Horiguchi, Kitasato University; Hajime Uno, Dana Farber Cancer Institute
9:05 AM
|
Multivariate Meta-Analysis Model for the Difference in Restricted Mean Survival Times
Isabelle R Weir, Boston University School of Public Health; Ludovic Trinquart, Boston University School of Public Health
9:35 AM
|
Real-Time Study Milestone Projection in Clinical Trials with Time-To-Event Endpoints
Yanping Liu, Merck & Co.; Gang Jia, Merck & Co.
9:50 AM
|
Statistical Precision of Time-to-Event Endpoint in Single Arm Observational Study Using Monte Carlo Simulation
Meijing Wu, AbbVie; Hongwei Wang, AbbVie Inc; Yabing Mai, AbbVie, Inc; Dajun Tian, Chiltern
11:20 AM
|
A Machine Learning (ML) Approach to Prognostic and Predictive Covariate Identification for Subgroup Analysis and Hypotheses Generation
David A James, Novartis
11:35 AM
|
Analysis of Stratified Clinical Trials with Time-To-Event Endpoints
Devan V Mehrotra, Merck & Co., Inc.; Shanjun Helian, Merck & Co., Inc.; Shu-Chih Su, Merck Research Labs
3:05 PM
|
Wednesday, 08/01/2018
|
Estimating Time-to-Event Characteristics via Longitudinal Threshold Regression Models - an Application to Cervical Dilation Progression
Caroline Mulatya, Emmes; Alexander C McLain , University of South Carolina; Bo Cai, University of South Carolina; James Hardin, University of South Carolina; Paul S Albert, National Cancer Institute
8:35 AM
|
Moving Beyond Longrank/Hazard Ratio Test/Estimation Approach in Cancer Clinical Trials
Hajime Uno, Dana Farber Cancer Institute; Miki Horiguchi, Kitasato University
8:35 AM
|
Distribution-Free Inference Methods for Threshold Regression
Mei-Ling Ting Lee, University of Maryland; George A Whitmore, McGill University
9:15 AM
|
Weighted Log-Rank Test for Time-To-Event Data in Immunotherapy Trials with Random Delayed Treatment Effect and Cure Rate
Shufang Liu, Astellas Pharma; Chenghao Chu, Indiana University, Fairbanks School of Public Health; Alan Rong, Data Science, Astellas Pharma Inc.
9:35 AM
|
Tools and Techniques for Blinded Data Reviews in Ongoing Clinical Trials
Suresh Ankolekar, Cytel Inc.; Hrishikesh Kulkarni, Cytel Inc.
9:55 AM
|
Time-To-Event Data with Time-Varying Biomarkers Measured Only at Study Entry, with Applications to Alzheimer's Disease
Catherine Lee, Kaiser Permanente Division of Research; Rebecca A. Betensky, Harvard School of Public Health
10:50 AM
|
Improving Testing and Description of Treatment Effect in Clinical Trials with Time-To-Event Outcomes
Song Yang, NHLBI/NIH
11:50 AM
|
|
|